HK Stock Market Move | KINTOR PHARMA-B (09939) rises over 12%; long-term safety trial of KX-826 for hair loss treatment completed, to be submitted to the National Medical Products Administration

KINTOR PHARMA-B (09939) share price moved higher, rising 12.70% as of press time to HK$1.42, with turnover of HK$523,300. On the news front, Kintor Pharma announced this morning that the long-term safety clinical trial of its self-developed, potentially first-in-class KX-826 tincture 1.0% for the treatment of androgenetic alopecia (AGA) has completed all subject follow-ups, demonstrating a favorable safety profile. As a necessary trial for KX-826's New Drug Application (NDA) submission, the results of this long-term safety clinical trial further confirm the long-term safety and efficacy of KX-826. The above results, together with materials including the positive Phase III clinical trial results announced in March 2026, will be included in the main NDA submission materials and will be submitted to the National Medical Products Administration in the near future.